Lantern Pharma Inc. (NASDAQ: LTRN) announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern’s RADR AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture and topological mapping, with benchmark-validated performance and accessibility designed to streamline drug discovery workflows and broaden access to advanced computational tools.
This move positions Lantern Pharma at the forefront of AI-driven drug discovery, offering a tool that can significantly reduce the time and cost associated with early-stage drug development. By providing a free, web-based platform, the company democratizes access to sophisticated computational analyses that were previously limited to large pharmaceutical companies with substantial resources. The LQM’s ability to process a single SMILES input and output a comprehensive developability profile could accelerate the identification of promising drug candidates, potentially bringing new therapies to market faster.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
Additionally, Lantern’s withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. This diversification into software-as-a-service (SaaS) offerings could provide a steady income stream beyond traditional drug development milestones.
For business and technology leaders, the expansion of predictBBB into an LQM underscores the growing role of AI in pharmaceutical R&D. It highlights a shift toward open-access computational tools that can be integrated into existing workflows, potentially reducing the barriers to entry for smaller biotech firms and academic researchers. The implications are broad: faster drug discovery cycles, lower costs, and a more collaborative ecosystem where data and insights are shared more freely.
Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. The company’s focus on AI and machine learning positions it to capitalize on the increasing convergence of technology and life sciences. As the industry moves toward more data-driven approaches, platforms like predictBBB and withZeta.ai could become essential tools for researchers worldwide.
To view the full press release, visit https://ibn.fm/XqWld. For more information about Lantern Pharma, visit the company’s newsroom at https://ibn.fm/LTRN.
